S. Padda

发表

Maintenance Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced, Nonsquamous, Non-Small Cell Lung Cancer

H. Wakelee, J. Riess, A. Logan, 2012, Cancer Investigation.

Combination of Immunotherapy and Antiangiogenic Therapy in Cancer-a Rational Approach.

K. Reckamp, S. Padda, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib.

K. Ramchandran, J. Neal, H. Wakelee, 2021, Clinical lung cancer.

Management of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline

Nofisat Ismaila, J. Bradley, F. Detterbeck, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Autoimmune Disease in Patients With Advanced Thymic Epithelial Tumors

H. Wakelee, S. Singhal, J. Hellyer, 2022, JTO clinical and research reports.

Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: brief report

H. Wakelee, C. Jacobs, A. Lopez-Anaya, 2013, Anti-cancer drugs.

Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases

Steven D Chang, K. Ramchandran, S. Hancock, 2021, Journal of Neuro-Oncology.

Perspectives on Acquired Resistance to PD-1 Axis Inhibitors in Patients with Non-Small Cell Lung Cancer.

H. Wakelee, D. Tseng, S. Padda, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Brief Report: Role of Consolidation Durvalumab in patients with EGFR and HER2 Mutant Unresectable Stage III NSCLC.

K. Ramchandran, J. Neal, H. Wakelee, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Lung Neuroendocrine Tumors: How Does Molecular Profiling Help?

A. Hendifar, T. Sun, S. Padda, 2022, Current Oncology Reports.

Pruritus as a Paraneoplastic Symptom of Thymoma.

J. Shrager, J. Neal, H. Wakelee, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Myocarditis Surveillance With High-Sensitivity Troponin I During Cancer Treatment With Immune Checkpoint Inhibitors

J. Neal, H. Wakelee, S. Srinivas, 2021, JACC. CardioOncology.

Genomic clustering analysis identifies molecular subtypes of thymic epithelial tumors independent of World Health Organization histologic type

H. Wakelee, S. Badve, Y. Gökmen-Polar, 2021, Oncotarget.

The role of induction therapy for thymic malignancies: a narrative review

J. Shrager, D. Patel, S. Padda, 2020, Mediastinum.

Programmed death receptor ligand-1 (PD-L1) expression in a thymoma (T) tissue microarray (TMA).

R. West, L. Tian, Y. Natkunam, 2014 .

Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer.

A. Chaudhuri, J. Neal, H. Wakelee, 2022, Cancer treatment and research communications.

Computed Tomography Features associated With the Eighth Edition TNM Stage Classification for Thymic Epithelial Tumors

Chuong D. Hoang, L. Tian, A. Leung, 2017, Journal of thoracic imaging.

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.

I. Weissman, H. Wakelee, B. Sikic, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Giant Magnetoresistive Nanosensor Analysis of Circulating Tumor DNA Epidermal Growth Factor Receptor Mutations for Diagnosis and Therapy Response Monitoring.

Alexander X. Lozano, S. Gambhir, J. Neal, 2021, Clinical chemistry.

Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions.

J. Neal, Jianchang Lin, L. Horn, 2020 .

Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non–Small Cell Lung Cancer

K. Ramchandran, H. Stehr, J. Neal, 2019, Clinical Cancer Research.

Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine

J. Aredo, S. Padda, 2018, Current Treatment Options in Oncology.

Clinical implications of KEAP1-NFE2L2 mutations in non-small cell lung cancer.

H. Wakelee, M. Diehn, J. Hellyer, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition

Ash A. Alizadeh, Aaron M. Newman, A. Newman, 2020, Cell.

Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling.

Ash A. Alizadeh, Aaron M. Newman, R. West, 2017, Cancer Discovery.

EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy.

K. Ramchandran, J. Neal, H. Wakelee, 2021, Clinical lung cancer.

KEAP1/NFE2L2 mutations predict lung cancer radiation resistance that can be targeted by glutaminase inhibition.

Ash A. Alizadeh, K. Ramchandran, J. Shrager, 2020, Cancer discovery.

Everolimus in the treatment of metastatic thymic epithelial tumors.

H. Wakelee, J. Hellyer, S. Padda, 2020, Lung cancer.

Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer

Ash A. Alizadeh, K. Ramchandran, J. Chabon, 2020, Nature Cancer.

Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.

K. Ramchandran, H. Stehr, J. Neal, 2019, Lung cancer.

Radiological tumor classification across imaging modality and histology

Carola-Bibiane Schönlieb, Ruijiang Li, Hiroki Shirato, 2021, Nature Machine Intelligence.

Diffuse High Intensity PD–L1 Staining in Thymic Epithelial Tumors

R. West, L. Tian, H. Kohrt, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database

J. Shrager, H. Wakelee, J. Riess, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pemetrexed in patients with thymic malignancies previously treated with chemotherapy.

R. West, J. Neal, H. Wakelee, 2015, Lung cancer.

Increased Galectin-1 Expression in Thymic Epithelial Tumors.

R. West, J. Neal, H. Wakelee, 2019, Clinical lung cancer.

MET inhibitors in combination with other therapies in non-small cell lung cancer.

J. Neal, H. Wakelee, S. Padda, 2012, Translational lung cancer research.

Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.

Summer S. Han, J. Shrager, J. Neal, 2019, Lung cancer.

Latest advances in management of small cell lung cancer and other neuroendocrine tumors of the lung.

H. Assi, S. Padda, 2020, Cancer treatment and research communications.

Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Socie

D. Metz, A. Sung, M. Soulen, 2020 .

Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC

Ash A. Alizadeh, Daniel K. Wells, C. Liu, 2020, Clinical Cancer Research.

Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion

T. Owonikoko, J. Weiss, M. Das, 2021, Advances in Therapy.

Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Non–Small-Cell Lung Cancer

J. Neal, H. Wakelee, T. Abbasi, 2021, JCO precision oncology.

A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non--small-cell lung cancer patients harboring ROS1 gene rearrangements.

J. Neal, H. Wakelee, J. Riess, 2013, Clinical lung cancer.

A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies

H. Wakelee, B. Sikic, A. Adjei, 2018, Cancer Chemotherapy and Pharmacology.

A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors

H. Wakelee, A. Colevas, J. Latz, 2011, Cancer Chemotherapy and Pharmacology.

Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer.

J. Neal, H. Wakelee, J. Aredo, 2021, Cancer treatment and research communications.

A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer

J. Neal, H. Wakelee, J. Kawashima, 2021, Cancer Chemotherapy and Pharmacology.

Durvalumab for Stage III EGFR-Mutated Non-Small Cell Lung Cancer After Definitive Chemoradiotherapy.

Summer S. Han, J. Neal, H. Wakelee, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies.

K. Ramchandran, J. Neal, H. Wakelee, 2019, Lung cancer.

RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer

J. Trepel, P. Ma, D. Morgensztern, 2019, British Journal of Cancer.

Early-stage non-small cell lung cancer: surgery, stereotactic radiosurgery, and individualized adjuvant therapy.

H. Wakelee, N. Trakul, B. Burt, 2014, Seminars in oncology.

Epidermal Growth Factor Receptor Mutation Status Confers Survival Benefit in Patients with Non-Small-Cell Lung Cancer Undergoing Surgical Resection of Brain Metastases: A Retrospective Cohort Study.

Summer S. Han, M. Hayden Gephart, Yuhao Huang, 2019, World neurosurgery.

CommNETs/NANETS guidelines for the diagnosis and management of patients with Lung Neuroendocrine Tumors: An international collaborative endorsement and update of the 2015 ENETS expert consensus guidelines.

D. Metz, A. Sung, M. Soulen, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Natural Disease History, Outcomes, and Co‐mutations in a Series of Patients With BRAF‐Mutated Non–small‐cell Lung Cancer

Summer S. Han, N. Myall, J. Neal, 2019, Clinical lung cancer.

BRAF: Novel Therapies for an Emerging Target

N. Myall, S. Padda, 2019, Targeted Therapies for Lung Cancer.

A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors.

I. Weissman, B. Sikic, C. Takimoto, 2018 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery

Mark M. Davis, P. A. Futreal, I. Weissman, 2021, Immunity.

Pretreatment biopsy for thymic epithelial tumors-does histology subtype matter for treatment strategy?

H. Wakelee, M. Keijzers, S. Padda, 2016, Journal of thoracic disease.

Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic non-small cell lung carcinoma.

K. Ramchandran, N. Myall, J. Neal, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: clinical characteristics and progression to carcinoid tumour

P. Kunz, D. Pancirer, Rishi Raj, 2021, European Respiratory Journal.

Determinants of Complete Resection of Thymoma by Minimally Invasive and Open Thymectomy: Analysis of an International Registry

J. Shrager, H. Wakelee, W. Scott, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Real-world risk of brain metastases in stage III non-small cell lung cancer in the era of PET and MRI staging

K. Ramchandran, R. Ko, J. Neal, 2023, Frontiers in Oncology.

Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction.

J. Neal, H. Wakelee, J. Riess, 2015, Lung cancer.

Response to comment on "Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes".

Summer S. Han, J. Shrager, J. Neal, 2019, Lung cancer.

Examination of factors associated with lymph node metastases in lung carcinoids: Results from a single institution retrospective cohort study.

L. Tian, G. Berry, P. Kunz, 2021, Lung cancer.

Osimertinib (Osi) plus necitumumab (Neci) in EGFR-mutant NSCLC: An ETCTN California cancer consortium phase I study.

S. Groshen, C. Paweletz, P. Jänne, 2019, Journal of Clinical Oncology.

Navigating the Landscape of Molecular Testing and Targeted Treatment of Non–Small Cell Lung Cancer

R. Harvey, S. Padda, 2016, Journal of the advanced practitioner in oncology.

141P Chemotherapy with or without immunotherapy or bevacizumab for EGFR-mutated lung cancer after progression on osimertinib

K. Ramchandran, J. Neal, H. Wakelee, 2021 .

Oral 1.01: Phase II trial of amrubicin in patients with previously treated advanced thymic malignancies

K. Ramchandran, J. Neal, H. Wakelee, 2015 .

Complications of ablative therapies in lung cancer.

H. Wakelee, B. Loo, J. Donington, 2008, Clinical lung cancer.

Phase II trial of single agent amrubicin (A) in patients (pts) with previously treated advanced thymic malignancies (TM).

K. Ramchandran, J. Neal, H. Wakelee, 2015 .

A Phase II First-Line Study of Gemcitabine, Carboplatin, and Bevacizumab in Advanced Stage Nonsquamous Non-small Cell Lung Cancer

P. Lavori, H. Wakelee, K. Ganjoo, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Brief Report: High Levels of CD47 Expression in Thymic Epithelial Tumors.

M. van de Rijn, Y. Natkunam, J. Neal, 2023, JTO clinical and research reports.

PS01.04: A Phase II Study of Etirinotecan Pegol (NKTR‐102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer: Topic: Medical Oncology

J. Neal, H. Wakelee, S. Soltys, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

P2.03b-012 A Phase II Study of Etirinotecan Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer: Topic: Brain Meta

J. Neal, H. Wakelee, S. Soltys, 2016 .

Left Anterior Descending Coronary Artery Radiation Dose Association with All-Cause Mortality in NRG Oncology Trial RTOG 0617.

R. Mak, R. Zakariaee, C. Guthier, 2022, International journal of radiation oncology, biology, physics.

P1.14-17 Identification of Molecular Subtypes of Thymic Epithelial Tumors and Novel Treatments Using a Computational Biological Model

H. Wakelee, S. Badve, Atul Kumar, 2018, Journal of Thoracic Oncology.

Implementation of a cloud-based electronic patient-reported outcome (ePRO) platform in patients with advanced cancer

K. Ramchandran, Robert W. Hsieh, J. Neal, 2021, Journal of Patient-Reported Outcomes.

Analysis of circulating tumor DNA in localized lung cancer for detection of molecular residual disease and personalization of adjuvant strategies.

Ash A. Alizadeh, Aaron M. Newman, A. Newman, 2017 .

Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study.

S. Groshen, C. Paweletz, H. Wakelee, 2022, Journal of Clinical Oncology.